Loading...

Veracyte

DB:12V
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
12V
DB
$947M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Veracyte has significant price volatility in the past 3 months.
12V Share Price and Events
7 Day Returns
-12.5%
DB:12V
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
338%
DB:12V
-10.2%
DE Biotechs
-6%
DE Market
12V Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Veracyte (12V) -12.5% -7.5% 31.4% 338% 326.9% 114%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 12V outperformed the Biotechs industry which returned -10.2% over the past year.
  • 12V outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
12V
Industry
5yr Volatility vs Market
Related Companies

12V Value

 Is Veracyte undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Veracyte to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Veracyte.

DB:12V Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:12V
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (2.67%))
1.32
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.32
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.32 * 5.96%)
8.1%

Discounted Cash Flow Calculation for DB:12V using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Veracyte is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:12V DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.1%)
2019 -7.60 Analyst x1 -7.03
2020 1.50 Analyst x1 1.28
2021 12.40 Analyst x1 9.82
2022 21.17 Est @ 70.69% 15.50
2023 31.65 Est @ 49.55% 21.44
2024 42.65 Est @ 34.75% 26.73
2025 53.06 Est @ 24.4% 30.76
2026 62.15 Est @ 17.15% 33.34
2027 69.66 Est @ 12.07% 34.56
2028 75.59 Est @ 8.52% 34.70
Present value of next 10 years cash flows $201.11
DB:12V DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $75.59 × (1 + 0.23%) ÷ (8.1% – 0.23%)
$962.69
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $962.69 ÷ (1 + 8.1%)10
$441.89
DB:12V Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $201.11 + $441.89
$643.00
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $643.00 / 41.11
$15.64
DB:12V Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:12V represents 0.87299x of NasdaqGM:VCYT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87299x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 15.64 x 0.87299
€13.65
Value per share (EUR) From above. €13.65
Current discount Discount to share price of €20.11
= -1 x (€20.11 - €13.65) / €13.65
-47.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Veracyte is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Veracyte's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Veracyte's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:12V PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.62
NasdaqGM:VCYT Share Price ** NasdaqGM (2019-04-18) in USD $23.03
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Veracyte.

DB:12V PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:VCYT Share Price ÷ EPS (both in USD)

= 23.03 ÷ -0.62

-37.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Veracyte is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Veracyte is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Veracyte's expected growth come at a high price?
Raw Data
DB:12V PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -37.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
63.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Veracyte, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Veracyte's assets?
Raw Data
DB:12V PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.95
NasdaqGM:VCYT Share Price * NasdaqGM (2019-04-18) in USD $23.03
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:12V PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:VCYT Share Price ÷ Book Value per Share (both in USD)

= 23.03 ÷ 1.95

11.8x

* Primary Listing of Veracyte.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Veracyte is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Veracyte's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Veracyte has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

12V Future Performance

 How is Veracyte expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Veracyte expected to grow at an attractive rate?
  • Veracyte's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Veracyte's earnings growth is expected to exceed the Germany market average.
  • Veracyte's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:12V Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:12V Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 63.9%
DB:12V Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 16.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:12V Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:12V Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 152 15 5 2
2020-12-31 133 4 -10 3
2019-12-31 115 -5 -17 4
DB:12V Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 92 -14 -23
2018-09-30 86 -18 -28
2018-06-30 80 -21 -31
2018-03-31 76 -23 -32
2017-12-31 72 -24 -31
2017-09-30 71 -22 -27
2017-06-30 72 -25 -26
2017-03-31 68 -27 -30
2016-12-31 65 -28 -31
2016-09-30 61 -27 -35
2016-06-30 55 -23 -38
2016-03-31 52 -27 -36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Veracyte's earnings are expected to grow significantly at over 20% yearly.
  • Veracyte's revenue is expected to grow by 16.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:12V Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Veracyte Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:12V Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.12 0.14 0.10 2.00
2020-12-31 -0.24 -0.05 -0.51 3.00
2019-12-31 -0.42 -0.34 -0.54 3.00
DB:12V Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.62
2018-09-30 -0.80
2018-06-30 -0.90
2018-03-31 -0.94
2017-12-31 -0.91
2017-09-30 -0.81
2017-06-30 -0.80
2017-03-31 -0.97
2016-12-31 -1.09
2016-09-30 -1.26
2016-06-30 -1.38
2016-03-31 -1.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Veracyte is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Veracyte's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Veracyte has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

12V Past Performance

  How has Veracyte performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Veracyte's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Veracyte does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Veracyte's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Veracyte's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Veracyte's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Veracyte Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:12V Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 92.01 -23.00 65.28 14.82
2018-09-30 85.85 -28.33 62.97 14.90
2018-06-30 79.91 -30.91 60.55 14.52
2018-03-31 75.56 -31.96 59.18 13.53
2017-12-31 71.95 -31.00 55.35 13.88
2017-09-30 70.61 -26.97 52.50 14.27
2017-06-30 71.70 -25.56 51.95 15.23
2017-03-31 67.97 -29.50 52.10 15.89
2016-12-31 65.09 -31.36 52.04 15.32
2016-09-30 60.87 -34.97 52.69 15.08
2016-06-30 54.60 -38.28 51.61 14.63
2016-03-31 51.84 -36.17 49.75 13.47
2015-12-31 49.50 -33.70 47.88 12.80
2015-09-30 47.66 -33.83 47.86 12.66
2015-06-30 45.16 -32.79 47.33 11.33
2015-03-31 41.93 -30.31 42.19 10.47
2014-12-31 38.19 -29.37 39.09 9.80
2014-09-30 32.83 -27.12 34.15 8.47
2014-06-30 28.59 -25.52 29.44 8.27
2014-03-31 24.98 -25.36 27.46 7.93
2013-12-31 21.88 -25.58 24.64 7.81
2013-09-30 19.50 -24.53 22.63 7.66
2013-06-30 17.13 -23.16 20.55 7.36
2013-03-31 14.54 -21.30 18.88 7.14
2012-12-31 11.63 -18.65 16.37 6.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Veracyte has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Veracyte has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Veracyte improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Veracyte's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Veracyte has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

12V Health

 How is Veracyte's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Veracyte's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Veracyte is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Veracyte's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Veracyte's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Veracyte Company Filings, last reported 3 months ago.

DB:12V Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 79.76 25.28 78.00
2018-09-30 79.42 25.27 77.85
2018-06-30 25.81 25.26 23.76
2018-03-31 30.01 25.25 27.15
2017-12-31 37.23 25.25 33.89
2017-09-30 42.82 25.38 41.20
2017-06-30 47.84 25.43 46.46
2017-03-31 53.35 25.47 51.51
2016-12-31 59.58 25.52 59.22
2016-09-30 30.01 24.89 31.70
2016-06-30 33.75 24.67 38.99
2016-03-31 43.31 24.45 47.46
2015-12-31 51.25 4.99 39.08
2015-09-30 57.81 5.00 46.12
2015-06-30 65.09 4.98 51.05
2015-03-31 35.08 4.95 25.80
2014-12-31 41.37 4.92 35.01
2014-09-30 48.28 5.01 44.00
2014-06-30 45.03 4.97 58.00
2014-03-31 50.29 4.93 64.24
2013-12-31 56.44 4.90 71.22
2013-09-30 2.70 4.86 15.43
2013-06-30 8.41 4.83 20.68
2013-03-31 -1.29 0.00 7.07
2012-12-31 4.90 0.00 14.00
  • Veracyte's level of debt (31.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (8.7% vs 31.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Veracyte has sufficient cash runway for more than 3 years based on current free cash flow.
  • Veracyte has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -21.4% each year.
X
Financial health checks
We assess Veracyte's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Veracyte has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

12V Dividends

 What is Veracyte's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Veracyte dividends.
If you bought €2,000 of Veracyte shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Veracyte's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Veracyte's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:12V Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:12V Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Veracyte has not reported any payouts.
  • Unable to verify if Veracyte's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Veracyte's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Veracyte has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Veracyte's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Veracyte afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Veracyte has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

12V Management

 What is the CEO of Veracyte's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bonnie Anderson
COMPENSATION $2,213,128
AGE 60
TENURE AS CEO 11.2 years
CEO Bio

Ms. Bonnie H. Anderson co-founded Veracyte, Inc. in 2008 and has served as its Chief Executive Officer and a Member of Board of Directors since February 2008. Ms. Anderson is Chairman of the Board at Veracyte since December 2016. She has extensive industry experience. From August 2013 to February 2017, Ms. Anderson also served as Veracyte’s President. Prior to joining Veracyte, Ms. Anderson was an independent strategic consultant from April 2006 to January 2008, including as a strategic consultant for Veracyte from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. She currently serves as a Director of Castle Biosciences, Inc. and as a Trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania.

CEO Compensation
  • Bonnie's compensation has increased whilst company is loss making.
  • Bonnie's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Veracyte management team in years:

2.2
Average Tenure
54
Average Age
  • The tenure for the Veracyte management team is about average.
Management Team

Bonnie Anderson

TITLE
Co-Founder
COMPENSATION
$2M
AGE
60
TENURE
11.2 yrs

Chris Hall

TITLE
President & COO
COMPENSATION
$1M
AGE
49
TENURE
2.2 yrs

Keith Kennedy

TITLE
CFO & Secretary
COMPENSATION
$793K
AGE
48
TENURE
2.3 yrs

Giulia Kennedy

TITLE
Chief Scientific Officer & Head of Scientific
AGE
59
TENURE
10.6 yrs

Ashish Kheterpal

TITLE
Chief Information Officer
TENURE
2.1 yrs

Angie McCabe

TITLE
Vice President of Investor Relations and Corporate Communications
TENURE
0.7 yrs

Jessica Meng

TITLE
Vice President of Marketing
TENURE
1.3 yrs

John Hanna

TITLE
Chief Commercial Officer
TENURE
2.2 yrs

Rick Kloos

TITLE
Senior Medical Director of Endocrinology
TENURE
7 yrs
Board of Directors Tenure

Average tenure and age of the Veracyte board of directors in years:

4.3
Average Tenure
63
Average Age
  • The tenure for the Veracyte board of directors is about average.
Board of Directors

Bonnie Anderson

TITLE
Co-Founder
COMPENSATION
$2M
AGE
60
TENURE
2.3 yrs

Karin Eastham

TITLE
Director
COMPENSATION
$101K
AGE
69
TENURE
6.3 yrs

Rob Epstein

TITLE
Director
COMPENSATION
$92K
AGE
63
TENURE
4.3 yrs

Tina Nova Bennett

TITLE
Director
COMPENSATION
$87K
AGE
64
TENURE
3.4 yrs

Kevin Gordon

TITLE
Director
COMPENSATION
$80K
AGE
55
TENURE
2.3 yrs

John Bishop

TITLE
Lead Independent Director
COMPENSATION
$104K
AGE
73
TENURE
2.3 yrs

Jesse Treu

TITLE
Director
COMPENSATION
$82K
AGE
71
TENURE
8.8 yrs

Evan Jones

TITLE
Director
COMPENSATION
$93K
AGE
61
TENURE
11.2 yrs

Fred Cohen

TITLE
Director
COMPENSATION
$91K
AGE
62
TENURE
12.3 yrs

Ed Liu

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • Veracyte insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Mar 19 Sell Evan Jones Individual 28. Feb 19 28. Feb 19 -75,000 €17.89 €-1,341,563
04. Mar 19 Sell Domain Associates, L.L.C. Company 28. Feb 19 04. Mar 19 -1,052,151 €18.76 €-18,931,656
02. Aug 18 Sell Domain Associates, L.L.C. Company 31. Jul 18 01. Aug 18 -500,000 €9.30 €-4,639,455
X
Management checks
We assess Veracyte's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Veracyte has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

12V News

Simply Wall St News

12V Company Info

Description

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson’s Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Details
Name: Veracyte, Inc.
12V
Exchange: DB
Founded: 2006
$841,836,144
41,108,741
Website: http://www.veracyte.com
Address: Veracyte, Inc.
6000 Shoreline Court,
Suite 300,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM VCYT Common Stock Nasdaq Global Market US USD 30. Oct 2013
DB 12V Common Stock Deutsche Boerse AG DE EUR 30. Oct 2013
Number of employees
Current staff
Staff numbers
270
Veracyte employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:36
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/02
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.